CJC 1295 with DAC is a modified GHRH peptide or growth hormone releasing hormone. CJC 1295 is sometimes referred to as a modified GRF 1-29 as it has a total of 29 amino acids (the 44 amino acids of GHRH long version with 15 removed). The DAC add on stands for Drug Affinity Complex and lengthens the lifespan of the peptide and prolonging its respective half-life. As it is a GHRH peptide research is being done on its ability to act on the pituitary gland by stimulating the release of somatostatin and growth hormone.
Availability: In stock
All the information below is strictly for research purposes only. Under no circumstance should this chemical be used for human consumption.
CJC 1295 is actually a modified form of GRF 1-29 belonging to the class of tetrasubtitued hormones that contain 30 amino acids. It can be considered an analog of GH releasing hormones, and the molecular mass is 3647.28. The formula is C165H269N47O46.
The CJC 1295 complex was the result of the work of Canadian scientists working to increase the half-life of the hormones that release the growth hormone. The first studies in a clinical setting regarding this compound were conducted in 2000. Another study involving the effectiveness and efficiency of the drug, as well as the safety, was done in 2006. It was double-blind, placebo-controlled, and randomized.
The involvement of DAC allows a greater ability to bind toward GHRH receptors. This protects the hormone from degrading.
Chemical and other safety information: